View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 25, 2018

Pfizer gets breakthrough status from FDA for cardiomyopathy drug

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Pfizer’s tafamidis to treat patients suffering from transthyretin cardiomyopathy, a rare condition characterised by progressive heart failure.

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Pfizer’s tafamidis to treat patients suffering from transthyretin cardiomyopathy, a rare condition characterised by progressive heart failure.

Tafamidis is an investigational drug and secured orphan drug designation for transthyretin cardiomyopathy in 2012 in the US and the European Union (EU).

In May last year, the product received the FDA fast track status, while the Japanese Ministry of Labor Health and Welfare granted it SAKIGAKE designation in March this year for the same indication.

Pfizer Global Product Development, Rare Disease senior vice-president Brenda Cooperstone said: “This designation is an important step forward in the path to bringing a potential new treatment option to those with transthyretin cardiomyopathy, a rare, fatal disease.We look forward to working with the FDA through this expedited process to fulfil an unmet patient need.”

“We look forward to working with the FDA through this expedited process to fulfil an unmet patient need.”

The FDA based its approval on the top-line results obtained from the Phase III Transthyretin Cardiomyopathy (ATTR-ACT) clinical trial.

Results revealed that tafamidis led to a statistically significant decrease in the combination of all-cause mortality and the number of cardiovascular-related hospitalisations.

Currently, transthyretin cardiomyopathy lacks specific, approved pharmacological treatments. The average life expectancy for people suffering from the disease is reported to be around three to five years after diagnosis.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU